Ontario’s Nuclea Energy Acquires Patent Portfolio from Insolvent New Brunswick Nuclear Firm Moltex Energy

Nuclea Energy, headquartered in Mississauga, Ontario, has acquired a portfolio of 89 current and pending patents from Moltex Energy, a nuclear technology developer based in New Brunswick. Moltex’s British parent company entered administration last year, prompting the sale of its intellectual property assets. While the purchase price was not officially disclosed, an April filing related to a planned public share offering—later withdrawn—indicated that Nuclea expected to pay approximately $11.5 million for the Moltex patents.

Moltex Energy’s technology is notable for its ability to generate additional energy from the waste produced by large conventional nuclear reactors. This approach has attracted substantial investment, with over $96 million committed to the project, much of it sourced from Canadian government funding. Moltex had been working toward deploying its technology at the Point Lepreau nuclear plant in New Brunswick, although commercial deployment remains a distant prospect.

Nuclea Energy has been developing its own nuclear technology, focusing on much smaller microreactors. Josef Freundorfer, Nuclea’s CEO, stated that acquiring Moltex’s intellectual property significantly expands the company’s technological potential and development pipeline.

In addition to the patent acquisition, Nuclea is pursuing a U.S. stock market listing through a merger with Mangoceuticals, a company that markets treatments for erectile dysfunction, baldness, and hormone therapy online. This strategic move aims to provide Nuclea with greater access to capital markets to support its nuclear technology development.

The acquisition represents a consolidation of nuclear technology assets within Canada’s emerging nuclear innovation sector. It also underscores the challenges faced by nuclear startups like Moltex, which despite significant investment, have struggled to bring their advanced reactor designs to commercial operation.

Nuclea’s expansion through the Moltex patent portfolio may accelerate its efforts to develop and commercialize microreactor technology, which is seen as a promising avenue for smaller-scale, flexible nuclear power generation.

The transaction highlights ongoing interest and investment in nuclear innovation in Canada, supported by both private and public funding sources, as the country seeks to diversify its energy mix and reduce carbon emissions.

The full details of the patent acquisition and Nuclea’s strategic plans remain subject to further disclosure as the company advances its business objectives and regulatory approvals.